EOLS Q3 2025 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$69M+12.9% YoY

Gross Profit

$46M66.5% margin

Operating Income

-$12M-16.7% margin

Net Income

-$16M-22.8% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-0.6%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$17M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$219M

Total Liabilities

$248M

Stockholders' Equity

-$29M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$61M	+12.9%
Gross Profit	$46M	$43M	+7.0%
Operating Income	-$12M	-$15M	+25.7%
Net Income	-$16M	-$19M	+17.9%

Revenue Segments

Product

$69M100%